2021
Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery
CIBULA, David, Jiri SLAMA, Lukas DOSTALEK, Daniela FISCHEROVA, Anna GERMANOVA et. al.Základní údaje
Originální název
Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery
Autoři
CIBULA, David (203 Česká republika, garant), Jiri SLAMA (203 Česká republika), Lukas DOSTALEK, Daniela FISCHEROVA (203 Česká republika), Anna GERMANOVA (203 Česká republika), Filip FRUHAUF (203 Česká republika), Pavel DUNDR (203 Česká republika), Kristyna NEMEJCOVA (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Silvie SEBESTOVA (203 Česká republika), Andrea BURGETOVA (203 Česká republika), Martina BORCINOVA (203 Česká republika) a Roman KOCIAN (203 Česká republika)
Vydání
British journal of cancer, London, Nature Publishing Group, 2021, 0007-0920
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 9.075
Kód RIV
RIV/00216224:14110/21:00120906
Organizační jednotka
Lékařská fakulta
UT WoS
000598704600001
Klíčová slova anglicky
cervical cancer; novel prognostic marker
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 8. 4. 2021 11:11, Mgr. Tereza Miškechová
Anotace
V originále
Background Models predicting recurrence risk (RR) of cervical cancer are used to tailor adjuvant treatment after radical surgery. The goal of our study was to compare available prognostic factors and to develop a prognostic model that would be easy to standardise and use in routine clinical practice. Methods All consecutive patients with early-stage cervical cancer treated by primary surgery in a single referral centre (01/2007-12/2016) were eligible if assessed by standardised protocols for pre-operative imaging and pathology. Fifteen prognostic markers were evaluated in 379 patients, out of which 320 lymph node (LN)-negative. Results The best predictive model for the whole cohort entailed a combination of tumour-free distance (TFD) <= 3.5 mm and LN positivity, which separated two subgroups with a substantially distinct RR 36% and 6.5%, respectively. In LN-negative patients, a combination of TFD <= 3.5 mm and adenosquamous tumour type separated a group of nine patients with RR 33% from the rest of the group with 6% RR. Conclusions A newly identified prognostic marker, TFD, surpassed all traditional tumour-related markers in the RR assessment. Predictive models combining TFD, which can be easily accessed on pre-operative imaging, with LN status or tumour type can be used in daily practice and can help to identify patients with the highest RR.